Grace Therapeutics, Inc. (GRCE) Balance Sheet

The current liquidity position suggests a precarious reliance on external capital markets, as the company lacks internal cash generation to fund its R&D pipeline. Investors should monitor the current ratio, which, while appearing high at 13.89, is largely a function of low current liabilities rather than an abundance of liquid assets relative to the burn rate.

The minimal investment in property, plant, and equipment, totaling only $12,000 as of 2026Q2, confirms an asset-light model that is entirely dependent on the regulatory and clinical viability of its lead assets. This concentration warrants further investigation into potential impairment risks should clinical milestones for GTX-104 fail to materialize as expected.

The persistent negative retained earnings suggest that the company has yet to establish a sustainable economic engine, forcing a reliance on equity financing that likely dilutes existing shareholders. The stability of the equity position appears fragile, as it is fundamentally tied to the company's ability to continue raising funds despite the lack of commercial revenue.